Healio
Healio
thin banner showing veins in the human eye

Euretina Congress
ByDavid Almeida, MD, MBA, PhD
ByMichela Cimberle
Fact checked byChristine Klimanskis, ELS

Read more

October 30, 2023
2 min watch
Save

VIDEO: Real-world data show good outcomes of fluocinolone acetonide implant

ByDavid Almeida, MD, MBA, PhD
ByMichela Cimberle
Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this Healio Video Perspective, David Almeida, MD, MBA, PhD, speaks about real-world study results of the fluocinolone acetonide intravitreal implant, a long-acting drug delivery system for diabetic macular edema.

In the study, presented at the Euretina congress, patients were shown to do well with Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences), irrespective of starting vision, with no new safety signals and significantly reduced treatment burden.

Sources/Disclosures

Collapse
Source:

Almeida D. 0.19 mg fluocinolone acetonide (FAc) implant leads to superior vision-, anatomical-, and treatment burden-related outcomes in eyes with better baseline visual acuity (≥20/40). Presented at: Euretina congress; Oct. 5-8, 2023; Amsterdam.

Disclosures: Almeida reports being a consultant, speaker and investigator for Alimera Sciences.

Read more about

drug delivery system
fluocinolone acetonide
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

 

Related Content